These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33651108)

  • 41. Factors Affecting Usage Levels and Trends of Innovative Oncology Drugs Upon and After Reimbursement Under Taiwan National Health Insurance: Interrupted Time Series Analysis.
    Liao KH; Ko BS; Chen LK; Hsiao FY
    Clin Transl Sci; 2020 Nov; 13(6):1288-1297. PubMed ID: 32583962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
    Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
    Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials.
    Ladanie A; Ioannidis JPA; Stafford RS; Ewald H; Bucher HC; Hemkens LG
    J Clin Epidemiol; 2018 Feb; 94():35-45. PubMed ID: 29146289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.
    Wong J; Motulsky A; Abrahamowicz M; Eguale T; Buckeridge DL; Tamblyn R
    BMJ; 2017 Feb; 356():j603. PubMed ID: 28228380
    [No Abstract]   [Full Text] [Related]  

  • 45. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.
    Kurzrock R; Gurski LA; Carlson RW; Ettinger DS; Horwitz SM; Kumar SK; Million L; von Mehren M; Benson AB
    Ann Oncol; 2019 Oct; 30(10):1647-1652. PubMed ID: 31373348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.
    Rachamin Y; Ackermann CJ; Senn O; Grischott T
    PLoS One; 2021; 16(11):e0259936. PubMed ID: 34780556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
    Cheng S; Cheung MC; Jiang DM; McDonald E; Arciero VS; Ezeife DA; Rahmadian A; Chambers A; Sabarre KA; Parmar A; Chan KKW
    J Natl Compr Canc Netw; 2019 Dec; 17(12):1489-1496. PubMed ID: 31805528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints.
    Smith N; Fu AC; Fisher T; Meletiche D; Pawar V
    J Med Econ; 2022; 25(1):1-6. PubMed ID: 34809504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detecting an overall survival benefit that is derived from progression-free survival.
    Broglio KR; Berry DA
    J Natl Cancer Inst; 2009 Dec; 101(23):1642-9. PubMed ID: 19903805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022.
    Luo X; Du X; Huang L; Guo Q; Lv X; Wang C; Liu H; Zhou Y; Xue X; Li Z; Liu J; Chow SC; Yang Y
    EClinicalMedicine; 2023 Sep; 63():102177. PubMed ID: 37662522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. International comparison of the factors influencing reimbursement of targeted anti-cancer drugs.
    Lim CS; Lee YG; Koh Y; Heo DS
    BMC Health Serv Res; 2014 Nov; 14():595. PubMed ID: 25432511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population.
    Eguale T; Buckeridge DL; Verma A; Winslade NE; Benedetti A; Hanley JA; Tamblyn R
    JAMA Intern Med; 2016 Jan; 176(1):55-63. PubMed ID: 26523731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. State insurance mandates and off-label use of chemotherapy.
    Smieliauskas F; Sharma H; Hurley C; de Souza JA; Shih YT
    Health Econ; 2018 Jan; 27(1):e55-e70. PubMed ID: 28726348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study.
    Etan T; Amir E; Tibau A; Yerushalmi R; Moore A; Shepshelovich D; Goldvaser H
    Cancer Treat Rev; 2020 Dec; 91():102113. PubMed ID: 33128993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?
    Chauca Strand G; Johansson N; Jakobsson N; Bonander C; Svensson M
    Clin Drug Investig; 2023 Aug; 43(8):621-633. PubMed ID: 37505421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.